Climb Bio

CLYM (NasdaqGM)

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapies for unmet needs in immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody for B-cell–mediated disorders, in Phase 2 for primary membranous nephropathy and immune thrombocytopenia, and Phase 1b for systemic lupus erythematosus. It also advances CLYM116, an anti-APRIL monoclonal antibody in preclinical development for IgA nephropathy. Incorporated in 2018, headquartered in Wellesley Hills, Massachusetts; formerly Eliem Therapeutics, renamed in October 2024.